Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjuvants for Coronavirus Vaccines
Zhihui Liang, Haoru Zhu, Xin Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 181

Showing 1-25 of 181 citing articles:

COVID-19 vaccines: The status and perspectives in delivery points of view
Jee Young Chung, Melissa N. Thone, Young Jik Kwon
Advanced Drug Delivery Reviews (2020) Vol. 170, pp. 1-25
Open Access | Times Cited: 347
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development
Yingzhu Li, Rumiana Tenchov, Jeffrey Smoot, et al.
ACS Central Science (2021) Vol. 7, Iss. 4, pp. 512-533
Open Access | Times Cited: 316
Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ali Pormohammad, Mohammad Zarei, Saied Ghorbani, et al.
Vaccines (2021) Vol. 9, Iss. 5, pp. 467-467
Open Access | Times Cited: 297
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Priyal Mistry, Fatima Barmania, Juanita Mellet, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 275
Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”
Rossella Talotta
Clinical Immunology (2021) Vol. 224, pp. 108665-108665
Open Access | Times Cited: 199
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
Markus Cornberg, Marı́a Buti, Christiane S. Eberhardt, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 4, pp. 944-951
Open Access | Times Cited: 198
Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants
Olga Vera‐Lastra, Alberto Ordinola Navarro, Maria Pilar Cruz Domiguez, et al.
Thyroid (2021) Vol. 31, Iss. 9, pp. 1436-1439
Closed Access | Times Cited: 194
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Vivek P. Chavda, Lalitkumar K. Vora, Anjali Pandya, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2619-2636
Open Access | Times Cited: 188
The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
Mehrdad Mohammadi, Mohammad Shayestehpour, Hamed Mirzaei
The Brazilian Journal of Infectious Diseases (2021) Vol. 25, Iss. 4, pp. 101606-101606
Open Access | Times Cited: 125
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Mattia Tiboni, Luca Casettari, Lisbeth Illum
International Journal of Pharmaceutics (2021) Vol. 603, pp. 120686-120686
Open Access | Times Cited: 104
Protein Cages: From Fundamentals to Advanced Applications
Thomas G. W. Edwardson, Mikail D. Levasseur, Stephan Tetter, et al.
Chemical Reviews (2022) Vol. 122, Iss. 9, pp. 9145-9197
Closed Access | Times Cited: 96
Biomaterials for Drug Delivery and Human Applications
Paolo Trucillo
Materials (2024) Vol. 17, Iss. 2, pp. 456-456
Open Access | Times Cited: 43
Protein subunit vaccines: Promising frontiers against COVID-19
Vivek P. Chavda, Eswara Naga Hanuma Kumar Ghali, Pankti C. Balar, et al.
Journal of Controlled Release (2024) Vol. 366, pp. 761-782
Closed Access | Times Cited: 15
Nanocarrier vaccines for SARS-CoV-2
Jatin Machhi, Farah Shahjin, Srijanee Das, et al.
Advanced Drug Delivery Reviews (2021) Vol. 171, pp. 215-239
Open Access | Times Cited: 89
Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature
Athanasios Siolos, Konstantina Gartzonika, Stelios Tigas
Metabolism Open (2021) Vol. 12, pp. 100136-100136
Open Access | Times Cited: 70
Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines
Puna Maya Maharjan, Sunghwa Choe
Vaccines (2021) Vol. 9, Iss. 9, pp. 992-992
Open Access | Times Cited: 67
Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
Seyed Davoud Jazayeri, Hui Xuan Lim, Kamyar Shameli, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 66
Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review
David Tak Wai Lui, Ka Kui Lee, Chi‐Ho Lee, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 64
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
Swarnali Das, Suvrendu Sankar Kar, Sovan Samanta, et al.
Immunologic Research (2022) Vol. 70, Iss. 3, pp. 289-315
Open Access | Times Cited: 64
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri, et al.
EBioMedicine (2022) Vol. 83, pp. 104217-104217
Open Access | Times Cited: 62
COVID-19 Vaccines: An Overview of Different Platforms
D.А. Kudlаy, Andrey Svistunov
Bioengineering (2022) Vol. 9, Iss. 2, pp. 72-72
Open Access | Times Cited: 61
Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations
Payam Tabarsi, Nassim Anjidani, Ramin Shahpari, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 9, pp. 1263-1271
Open Access | Times Cited: 46
Thyrotoxicosis following SARS-COV-2 vaccination: a case series and discussion
Begoña Pla Peris, Agustín Ángel Merchante Alfaro, Francisco Javier Maravall Royo, et al.
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 5, pp. 1071-1077
Open Access | Times Cited: 40
Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial
Payam Tabarsi, Nassim Anjidani, Ramin Shahpari, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 2, pp. 215-220
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top